Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib plus Lasetelet in First-line EGFR-mutated Advanced NSCLC (Phase II)
ChiCTR2400083981Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Progression-Free Survival. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400083981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083981.